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Abstract
Background:  Artemisinin combination therapy (ACT) is now the recommended first-line
treatment for falciparum malaria throughout the world. Initiatives to eliminate malaria are critically
dependent on its efficacy. There is recent worrying evidence that artemisinin resistance has arisen
on the Thai-Cambodian border. Urgent containment interventions are planned and about to be
executed. Mathematical modeling approaches to intervention design are now integrated into the
field of malaria epidemiology and control. The use of such an approach to investigate the likely
effectiveness of different containment measures with the ultimate aim of eliminating artemisinin-
resistant malaria is described.
Methods: A population dynamic mathematical modeling framework was developed to explore the
relative effectiveness of a variety of containment interventions in eliminating artemisinin-resistant
malaria in western Cambodia.
Results: The most effective intervention to eliminate artemisinin-resistant malaria was a switch of
treatment from artemisinin monotherapy to ACT (mean time to elimination 3.42 years (95% CI
3.32–3.60 years). However, with this approach it is predicted that elimination of artemisinin-
resistant malaria using ACT can be achieved only by elimination of all malaria. This is because the
various forms of ACT are more effective against infections with artemisinin-sensitive parasites,
leaving the more resistant infections as an increasing proportion of the dwindling parasite
population.
Conclusion:  Containment of artemisinin-resistant malaria can be achieved by elimination of
malaria from western Cambodia using ACT. The "last man standing" is the most resistant and thus
this strategy must be sustained until elimination is truly achieved.
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Background
The Thai-Cambodian border area is historically the source
of the global diaspora of anti-malarial drug resistance.
Resistance to chloroquine and sulphadoxine-pyrimeth-
amine in Plasmodium falciparum originated there, spread
across Asia and Africa, and caused millions of deaths [1].
The increase in malaria mortality is now being reversed
where effective vector control measures and anti-malari-
als, principally artemisinin-based combination therapy
(ACT), are being deployed [2]. Current initiatives to elim-
inate malaria are critically dependent on their continued
efficacy.
In the 2006, WHO Guidelines for the Treatment of
Malaria [3] ACT became the recommended first-line treat-
ment for uncomplicated Plasmodium falciparum malaria in
all endemic areas. Intravenous artesunate became the
treatment of choice for severe malaria, except for children
in Africa (where studies are in progress) [3,4]. These rec-
ommendations for the large-scale use of artemisinin
derivatives were based on their excellent tolerability,
safety, and reliable efficacy. Recent data from western
Cambodia provides the first objective evidence that effi-
cacy of this essential drug class may be declining [5-7].
Cure rates with ACT have been worse in this area than any-
where else. This was attributed initially to resistance to the
partner drugs (mefloquine [8] and lumefantrine [9]), but
recent detailed studies show that parasite clearance times
following standard doses of artesunate in uncomplicated
falciparum malaria are significantly longer than elsewhere
in the world [5-7]. Artemisinins have been available as
monotherapies in western Cambodia for over 30 years in
a variety of forms and doses, whereas in most countries,
other than China where they were discovered, they have
been a relatively recent introduction [5]. The extended
period of often sub-optimal use and the genetic back-
ground of parasites from this region have created a dan-
gerous milieu [10]. If reduced in-vivo  parasitological
efficacy is the first sign of artemisinin resistance then
immediate action should be taken to prevent the spread of
these parasites elsewhere [11]. Loss of these drugs would
be a disaster for global malaria control and elimination
prospects as there are no obvious replacements emerging
from the development pipeline in the near future [12].
Fortunately malaria in western Cambodia can be consid-
ered as affecting a land island with no major contiguous
connections to other malaria endemic areas [13]. The pri-
vate sector is the main source of anti-malarial drugs in
Cambodia. Self-treatment with short (inadequate)
courses of oral artemisinin monotherapies has been com-
mon [14]. Many other anti-malarials are available, includ-
ing artesunate-mefloquine (MAS3), the nationally
recommended first-line treatment for falciparum malaria
since 2000. Several different interventions to contain and
ideally eliminate the threat of artemisinin resistance are
under consideration by the national malaria control pro-
grammes, the World Health Organization and malaria
community [6].
The current debate centres around a number of questions
including:
￿ Which anti-malarial should be used in different situa-
tions? Under consideration are atovaquone plus pro-
guanil (AP) and/or dihydroartemisinin and piperaquine,
both given for three days, plus one "gametocytocidal"
dose of primaquine (APP).
￿ Who should receive these treatments? a) symptomatic
patients only b) anyone with a positive blood film for
malaria ('Mass Screening and Treatment', MSAT) c) the
general population regardless of symptoms or blood film
positivity ('Mass Drug Administration', MDA).
￿ How long will an intervention need to be continued?
Longer interventions are more costly and difficult to sus-
tain. The cost-effectiveness of each proposed intervention
and the consequences of premature cessation have not yet
been quantified.
￿ What is the added value of insecticide-treated bed nets
(ITNs)?
These choices must be made now on the basis of available
evidence to reduce the risk of resistance spreading west-
ward. Containment beyond the western border of Thai-
land is probably impossible. There are insufficient data
and insufficient time to undertake adequately powered
clinical studies to inform these urgently needed decisions,
so the relevant agencies are currently relying upon expert
opinion. A mathematical modeling framework (see Figure
1 and Additional Files 1 and 2) of malaria in Cambodia
focusing on the population dynamics of artemisinin
resistance and its control was, therefore, developed to aid
decision making [15].
Methods
The structure of the basic population dynamic model is
shown in Figure 1. It is based on the malaria parasite life-
cycle in humans and the responses of the various stages to
drug treatment. A deterministic structure was used to con-
duct sensitivity analyses and to make an initial assessment
of the relative effectiveness of the various containment
interventions proposed. Results of interest were then con-
firmed in a stochastic framework with the same structure
and parameters. Seasonality was incorporated to reflect
the highly seasonal transmission intensity in this region.
In order to maintain simplicity and therefore flexibility
and interpretability of the model, a number of assump-
tions were made (Additional file 1-Table S1). The modelMalaria Journal 2009, 8:31 http://www.malariajournal.com/content/8/1/31
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Schematic diagram of the structure of the mathematical modeling framework Figure 1
Schematic diagram of the structure of the mathematical modeling framework. The structure of the model is built 
up as follows: natural history and pharmacodynamics incorporated as a repeating unit (A) with four compartments – suscep-
tible people, people with liver stage infection, people with noninfectious blood stage infection and people with infectious 
(blood) stage infection, rates of flow between these compartments (βI/N, δ, γ and σ) and rates of recovery due to each of 
artesunate and piperaquine treatment (cBda, cIda, cBdb and cIdb) (Additional file 1- Table S2) is shown. The times to recovery 
(1/rate) following treatment are then adjusted by a multiplying factor (erada or erbdb) (0 ≤ e ≤ 1) depending on the degree of 
resistance to each drug, giving three possible linked variants of unit A (resistant to no drug, artesunate only and piperaquine 
only) making up a repeating pattern (B). Finally the population dynamics of transmission is shown in (C). This consists of multi-
ple repetitions of (B) with different rates of flow between them at different time points depending on which treatments and 
interventions are used. For example, for individuals with blood stage infections to begin treatment with ACT, they will move 
from the 'No drugs' box (1) to the equivalent parts of an 'ACT' box (2) at a rate determined by the time to begin treatment. 
The dynamics in the 'ACT' box are different from the 'No drugs' box as these individuals will be subjected to faster rates of 
recovery due to the ACT. Each box is also subject to pharmacokinetic dynamics independent of infection dynamics. This is in 
the form of waning pharmacodynamic drug effect over time ('loss of...') with sequential loss of DHA and then piperaquine. This 
results in a percentage of the entire unit moving to a new box 'Piperaquine' (3) which again has different dynamics representing 
the effect of piperaquine on recovery rates. Interventions shown here are elimation of artemisinin monotherapy and replace-
ment with ACT ('Switch to ACT') and MSAT and MDA with ACT. Each circle represents a population exposed to a particular 
drug or combination. Key: ACT = dihydroartemisinin/piperaquine combination therapy, Rx = treatment, DHA = dihydroar-
temisinin. (For more details, please see the Full Model Code in Additional File 2.)Malaria Journal 2009, 8:31 http://www.malariajournal.com/content/8/1/31
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was run from 1960–1975 to achieve a treatment free equi-
librium for a population prevalence of malaria parasitae-
mia (of any density) of 16%. This equilibrium was
calculated by the numerical solution of the treatment-free
sub-model equilibrium equations. Artesunate mono-
therapy was then introduced as the only treatment in
1975 (when artesunate was first used in Cambodia). A
single patient with artemisinin-resistant infection was
introduced in 1980. By 2008, the mean population prev-
alence of malaria in the high transmission season was
7.5% (compared to estimate from field data of 7.4% [13]
and the prevalence of artemisinin resistance in the model
was 10.6% (expert opinion estimates this to be around
10%) (this whole process is shown in Figure 2). The inter-
ventions were then introduced in 2009, to reflect the cur-
rent plans for containment.
The full list of parameters is shown in Table S2 (Addi-
tional File 1). The interventions that were introduced into
the model, alone and in combination, were:
a) Eliminating the use of artemisinin monotherapies
(artesunate in the model) and replacing them with ACT in
the private sector (i.e. for symptomatic patients only).
b) One or more annual three-month pulses of MSAT with
ACT or AP during the low transmission season.
c) One or more annual three-month pulses of MDA with
ACT or AP during the low transmission season.
d) As for b) and c) plus primaquine.
e) Distribution of ITNs (or comparable treated materials).
For each pulse of MDA and MSAT, each patient received a
three-day course of treatment (ACT or AP) on one occa-
sion only.
Results
Continuing availability of artesunate monotherapy
The model predicts that if there is no intervention, and use
of artemisinin monotherapies continues, there will be an
exponential rise in the proportion of resistant infections
and a slowly increasing prevalence of infection. By 2030,
the model predicts that the prevalence of malaria will
have doubled compared to 2008 and resistance to the
artemisinins will be approaching 100% (Figure 2).
Eliminating artemisinin resistance
The model predicts that it is possible to achieve elimina-
tion of artemisinin resistance using medications alone,
but in all scenarios elimination of malaria is required in
order to eradicate artemisinin resistance.
The most effective single intervention to achieve elimina-
tion of artesunate resistance is the elimination of inade-
quate courses of artesunate monotherapy and
replacement with ACT with high coverage (a). This would
be achieved if all monotherapies were actively replaced by
ACT in the private sector and there was adequate contin-
ued supply of good quality, affordable ACT. Using this
strategy and with an introduction of the ACT over three
months it is possible in the model to achieve elimination
of artemisinin-resistant malaria within four years in 70%
of cases (mean time to elimination 3.42 years (95% CI
3.32–3.60 years), (Figure 3). The stochastic model was
run 200 times and elimination was achieved with this
strategy in 100% of cases, suggesting this strategy is highly
likely to be successful. The downside is that, because a lot
of artemisinin is being used, the prevalence of artemisinin
resistance just before elimination drastically increases. It
reaches 82% in the deterministic model and 100% in 58%
of cases in the stochastic model (Figure 4 illustrates one of
these cases).
The proportion of infections resistant to artemisinins then
remains at this high level provided that there is no impor-
tation of new infections from elsewhere. This suggests that
if an intervention were to fail, or was discontinued prema-
turely, the prevalence of resistance would be much higher
subsequently than if no intervention had taken place.
If artemisinin monotherapies remain available, one three-
month pulse of MSAT or MDA with either ACT or AP (b
or c) reaching 80% of the infected population would have
a significant short-term impact, but a negligible long-term
Effect of continuing availability and use of artemisinin mono- therapy on the total number of malaria infections (black line),  the number of artemisinin-resistant infections (red line) and  percentage of infections resistant to artemisinin (red dotted  line) over time Figure 2
Effect of continuing availability and use of artemisinin 
monotherapy on the total number of malaria infec-
tions (black line), the number of artemisinin-resist-
ant infections (red line) and percentage of infections 
resistant to artemisinin (red dotted line) over time. 
Artesunate monotherapy is introduced as treatment in 1975 
and a single artemisinin-resistant infection in 1980.Malaria Journal 2009, 8:31 http://www.malariajournal.com/content/8/1/31
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impact on the numbers of resistant infections. This is
because although such interventions reduce infections
they are not sufficient to completely interrupt transmis-
sion at the population level. For example, AP MSAT is the
most effective of these strategies but one pulse of this only
produces a 35% reduction in total malaria infections and
31% reduction in the number of artemisinin-resistant
infections. If a three-month pulse of MSAT or MDA is used
in addition to a switch to ACT for treatment then there is
negligible additional effect. Repeated annual three-month
pulses of MSAT or MDA are also insufficient to achieve
elimination when used alone, regardless of the drugs
used. This is because the number of infections increases
again in the other nine months of the year with an increas-
ing proportion of artemisinin-resistant infections each
time due to ongoing artemisinin use. When used in this
way, MSAT is more effective than MDA and AP has greater
impact than ACT. For example, the maximum effect of
long-term annual MSAT with AP on the numbers of
artesunate resistant infections is at two years. At this time,
the decrease in malaria infections is 55% and artemisinin-
resistant infections have fallen to 39% compared to 2009.
Following this trough, the number of artemisinin-resist-
ant infections rises again although the total number of
malaria infections does not reach a minimum until after 7
years (80% below that for 2009). For comparison, if ACT
MSAT is used, the lowest number of artesunate resistant
infections is in the first year with a 32% decrease in
malaria prevalence and 31% fall in artesunate resistant
infections compared to 2009. The number of artesunate
resistant infections then increases again but the total
number of malaria infections does not reach a minimum
until after five years (61% lower than in 2009).
If the MDA or MSAT is carried out in the peak transmis-
sion season for malaria, the maximum decrease in the
number of artemisinin-resistant infections is half that
which can be achieved in the low transmission season.
The frequency of MSAT and MDA was varied and it was
found that if carried out twice a year then elimination
became possible. If MSAT with AP was undertaken at a
maximum of four times a year (it takes three months to
complete one round) then elimination can be achieved in
eight years. All this is predicated upon resistance not
emerging to AP.
The addition of primaquine to annual MDA or MSAT (d)
reduces the trough in the number of artemisinin-resistant
infections by 20% and the total number of malaria infec-
tions by 40%. This extra effect is still insufficient to
achieve elimination.
Assuming that malaria vectors bite after people are in or
near their beds, then ITNs (e) have a relatively large effect
and accelerate the eradication of resistance. The longer
that nets are used for, the larger the effect; for example, if
the effect of bed nets lasts around four years (the equiva-
lent of long-lasting treated nets) and they reduce transmis-
sion by 30%, then time to eradication is reduced by about
50%. Thus a modest, but sustained, protective effect from
bed nets or other transmission blocking methods can
have a significant impact on the time to elimination.
Effect of eliminating artesunate monotherapy and replace- ment with ACT in 2009 for treatment of symptomatic cases  on the total number of malaria infections (black line), the  number of artemisinin-resistant infections (red line) and the  percentage of infections resistant to artesunate (dotted lines,  pink = artesunate red = ACT) (mean-field approximation) Figure 3
Effect of eliminating artesunate monotherapy and 
replacement with ACT in 2009 for treatment of 
symptomatic cases on the total number of malaria 
infections (black line), the number of artemisinin-
resistant infections (red line) and the percentage of 
infections resistant to artesunate (dotted lines, pink 
= artesunate red = ACT) (mean-field approxima-
tion).
Example of a single stochastic output illustrating the effect of  a switch of treatment to ACT in 2009 Figure 4
Example of a single stochastic output illustrating the 
effect of a switch of treatment to ACT in 2009.Malaria Journal 2009, 8:31 http://www.malariajournal.com/content/8/1/31
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When a fitness cost of artemisinin resistance is included in
the model, the rate of increase of resistant infections is
slower (around 33% slower for fitness cost of 5%) and the
rate of elimination by an intervention is marginally faster
(19% for a fitness cost of 5%). The fitness cost must be less
than 7.5% for the number of artemisinin-resistant infec-
tions to increase over time.
Sensitivity analysis
For all interventions, the following were varied in turn:
the coverage with ACT from 0 to 100%, the effectiveness
of dihydroartemisinin and piperaquine against resistant
infections and the cost of piperaquine resistance between
0 and 100%, the cost of artemisinin resistance in terms of
fitness between 0 and 5%, the average time to receive anti-
malarials during an intervention from 7 to 90 days, and
time to natural recovery from infection (i.e. without treat-
ment) from 60 to 200 days. Duration of drug effect was
also varied for atovaquone from 10–15 days and for pip-
eraquine from 20–30 days.
The model was most sensitive to ACT coverage, effective-
ness of artemisinins against resistant infections, fitness
cost of ACT resistance, and time to receive anti-malarials.
There was a threshold coverage with ACT of 47% below
which the time to eradication was more than a decade.
With ACT coverage of <28%, elimination was impossible.
The effectiveness of artemisinins against resistant infec-
tions was determined from field data to reflect current
phenotypes [7] but it is likely that this will decrease over
time with continued use of artemisinins. The model pre-
dicts that if this effectiveness halves compared to 2009,
time to eradication will take 50% longer. If time to receive
anti-malarials (ACT or AP) doubles (from 16 to 32 days
after developing blood stage infection) time to elimina-
tion increases more than threefold, whereas if people
receive anti-malarials in half the time (eight days after
blood stage infection), time to elimination is three times
less. The time to eradication was unaffected by natural
recovery rate from infection, and the effectiveness of and
fitness cost of resistance to piperaquine. Changing the
duration of atovaquone and piperaquine effect had mini-
mal impact on the results. To explore the effect of synergy
between the components of ACT, the rate of clearance of
infection was varied from 1/3 days-1 to 1/7 days-1. This
had negligible effect on the time to elimination but
decreasing the clearance rate of gametocytes by ACT to 1/
7 days-1 decreased the percentage of artemisinin-resistant
infections at the time of elimination from 82% to 54%.
Discussion
Using a relatively simple modeling framework, it was
shown that eliminating the use of artemisinin mono-
therapy and replacing it with ACT can be sufficient to
eradicate artemisinin-resistant malaria in Cambodia.
Short-term or pulsed interventions such as MSAT or MDA
are not sufficiently effective to achieve eradication on
their own. Their additional effect, when added to an elim-
ination of monotherapy and replacement with ACT, is so
small that it is questionable whether they should be con-
sidered at all. AP is more effective than ACT when used in
MSAT or MDA but the additional impact of MSAT or
MDA, when used in addition to elimination of artemisi-
nin monotherapy and switching treatment to ACT, is
small. AP also has the disadvantages of slow clinical
responses, high purchase cost, and a low threshold for
high-grade resistance and is not therefore being consid-
ered for routine first-line treatment of symptomatic cases.
In stark contrast, ITNs greatly accelerate the impact of
ACT, provided they are effective. Some vectors in this
region bite very early in the evening and where these pre-
dominate, ITNs would have marginal benefits. Assuming
they are effective the ideal combination appears to be
long-lasting insecticide-treated bed nets and high cover-
age with ACT treatment.
If ACTs are used to eliminate artemisinin-resistant malaria
then these models provide an important caveat. Elimina-
tion of artemisinin-resistant malaria requires the elimina-
tion of all malaria as the last few infections to be cleared
are almost all resistant. ACT provides a selective pressure
for artemisinin resistance, especially in infections with
concomitant resistance to the partner drug (piperaquine).
The result of this is that ACT produces an increase in the
proportion of infections resistant to artemisinin every year
that it is used. Monitoring studies would indicate an
increase in resistance as incidence and prevalence fell. Any
intervention aimed at achieving elimination must, there-
fore, be used continually through to elimination as dis-
continuing its use too early would allow the number of
infections to increase again but this time a higher propor-
tion of resistant infections would be present than if no
intervention had been attempted.
Conclusion
The model presented here assumes that resistance to
artemisinin monotherapy has already emerged on the
Thai-Cambodian border. Early intervention has a greater
chance of preventing its spread than delaying until higher
levels of resistance develop (which would be more diffi-
cult to contain). Even if resistance is not present, eliminat-
ing artemisinin monotherapies and replacing them with
an effective ACT with high coverage should remove the
potential threat of emergence and spread of resistance,
thus increasing the effective life span of this important
class of anti-malarial drugs worldwide. This modeling
exercise provides some general guidelines and principles
on elimination of artemisinin resistance using ACT, AP,
primaquine and ITNs. In summary, rapid, efficient and
sustained action could combat the significant risk thatPublish with BioMed Central    and   every 
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artemisinin resistance poses to global public health.
Attacking the last man standing is a bold strategy since
failure could result in a far more resistant population than
existed before the intervention. This strategy, therefore,
requires a steadfast commitment from donors to ensure
success.
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